WINT vs. JBIO, BMRA, AEON, OBSV, GTBP, CVM, CHRO, CYCC, GNPX, and PMCB
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Jade Biosciences (JBIO), Biomerica (BMRA), AEON Biopharma (AEON), ObsEva (OBSV), GT Biopharma (GTBP), CEL-SCI (CVM), Chromocell Therapeutics (CHRO), Cyclacel Pharmaceuticals (CYCC), GENPREX (GNPX), and Nuvilex (PMCB). These companies are all part of the "pharmaceutical products" industry.
Windtree Therapeutics vs. Its Competitors
Jade Biosciences (NASDAQ:JBIO) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.
Jade Biosciences is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Windtree Therapeutics had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Windtree Therapeutics and 2 mentions for Jade Biosciences. Windtree Therapeutics' average media sentiment score of 1.29 beat Jade Biosciences' score of 0.94 indicating that Windtree Therapeutics is being referred to more favorably in the news media.
Jade Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Jade Biosciences presently has a consensus target price of $14.00, suggesting a potential upside of 40.14%. Windtree Therapeutics has a consensus target price of $350.00, suggesting a potential upside of 67,716.31%. Given Windtree Therapeutics' higher possible upside, analysts plainly believe Windtree Therapeutics is more favorable than Jade Biosciences.
29.3% of Windtree Therapeutics shares are owned by institutional investors. 24.9% of Jade Biosciences shares are owned by company insiders. Comparatively, 0.3% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Jade Biosciences' return on equity of -60.01% beat Windtree Therapeutics' return on equity.
Summary
Jade Biosciences beats Windtree Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:WINT) was last updated on 7/1/2025 by MarketBeat.com Staff
Free WINT Stock Alerts